STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 72 filers reported holding STOKE THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,239 | -99.9% | 1,076 | -99.6% | 0.00% | -100.0% |
| Q2 2022 | $3,294,000 | +128.9% | 249,364 | +264.8% | 0.01% | +200.0% |
| Q1 2022 | $1,439,000 | -91.8% | 68,350 | -90.7% | 0.00% | -90.9% |
| Q4 2021 | $17,629,000 | -5.7% | 734,835 | -0.0% | 0.03% | -8.3% |
| Q3 2021 | $18,696,000 | -34.8% | 734,882 | -13.7% | 0.04% | -32.1% |
| Q2 2021 | $28,674,000 | -15.4% | 851,875 | -2.3% | 0.05% | -19.7% |
| Q1 2021 | $33,878,000 | -43.5% | 872,264 | -10.0% | 0.07% | -46.3% |
| Q4 2020 | $59,999,000 | +115.7% | 968,811 | +16.7% | 0.12% | +89.2% |
| Q3 2020 | $27,810,000 | +40.5% | 830,400 | 0.0% | 0.06% | +32.7% |
| Q2 2020 | $19,788,000 | +4.1% | 830,400 | 0.0% | 0.05% | -12.5% |
| Q1 2020 | $19,016,000 | -13.2% | 830,400 | +7.4% | 0.06% | +14.3% |
| Q4 2019 | $21,904,000 | +77.0% | 773,417 | +34.3% | 0.05% | +63.3% |
| Q3 2019 | $12,378,000 | +268.9% | 576,000 | +400.9% | 0.03% | +275.0% |
| Q2 2019 | $3,355,000 | – | 115,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 17,161,713 | $666,561,000 | 74.20% |
| RTW INVESTMENTS, LP | 3,644,248 | $141,543,000 | 2.21% |
| Redmile Group, LLC | 2,544,062 | $98,811,000 | 1.39% |
| Cormorant Asset Management, LP | 1,437,807 | $55,844,000 | 1.24% |
| ACUTA CAPITAL PARTNERS, LLC | 45,000 | $1,748,000 | 0.63% |
| SPHERA FUNDS MANAGEMENT LTD. | 150,729 | $5,854,000 | 0.45% |
| HighVista Strategies LLC | 13,692 | $532,000 | 0.40% |
| Birchview Capital, LP | 15,000 | $583,000 | 0.35% |
| Perceptive Advisors | 671,978 | $26,100,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,265,950 | $49,169,000 | 0.26% |